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Abstract
Using longitudinal survey data collected in collaboration with a treatment program, this paper
estimates the economic impacts of antiretroviral treatment. The responses in two outcomes are
studied: (1) labor supply of treated adult AIDS patients; and (2) labor supply of individuals in
patients’ households. Within six months after treatment initiation, there is a 20 percent increase in
the likelihood of the patient participating in the labor force and a 35 percent increase in weekly
hours worked. Young boys in treated patients’ households work significantly less after treatment
initiation, while girls and adult household members do not change their labor supply.
I. Introduction
Sub-Saharan Africa is home to 25 million of the nearly 40 million people living with HIV/
AIDS worldwide (UNAIDS 2006). In the next decade, AIDS-related mortality in Africa has
the potential to generate growing numbers of orphans (already 12 million), while also
shortening life expectancy to below 40 years in a number of countries. Following increases
in donor support and substantial reductions in the prices of medicines, antiretroviral (ARV)
therapy has recently become an important part of the policy response to combat AIDS.1 As
of December 2005, roughly eight hundred thousand HIV-positive individuals were receiving
ARV therapy in sub-Saharan Africa (WHO 2006). Since this represents only 17 percent of
the number of people needing treatment, scaling-up of treatment programs poses a major
challenge in many countries.2 At the same time, however, some have questioned the
investment in ARV therapy since most low-income countries have limited resources and
many competing needs (Marseille, Hofmann, and Kahn 2002; Kremer 2002; Canning 2006).
Numerous studies have shown that ARV therapy dramatically reduces morbidity and
mortality among HIV-infected individuals, in both industrialized countries (Hammer et al.
1997, Hogg et al. 1998; Palella et al. 1998) and developing countries (Laurent et al. 2002;
Marins et al. 2003; Koenig, Leandre, and Farmer 2004; Coetzee et al. 2004; Wools-
Kaloustian et al. 2006). These health benefits have the potential to significantly improve
economic well-being, as suggested by a growing literature that shows linkages between
health and income in developing countries.3 While this literature examines the economic
impacts of several dimensions of health such as nutritional status and morbidity, it provides
little guidance when it comes to a highly debilitating and chronic disease like HIV/AIDS.
One exception is the recent study by Fox et al. (2004), who analyze retrospective data from
a Kenyan tea estate and find significant declines in the labor productivity of HIV-positive
1For example, in 2003 the World Health Organization (WHO) launched the prominent “3 by 5” campaign, with the goal of treating
three million people by 2005 (WHO 2003).
2As explained below, not all HIV-positive individuals are currently in need of ARV therapy.
3See Strauss and Thomas (1998), Ruger, Jamison, and Bloom (2001), and Thomas and Frankenberg (2002) for reviews and
discussions of the micro-economic literature on linkages between health and income.
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workers prior to their death or medical retirement. However, the extent to which treatment
can reverse such declines in labor productivity remains to be determined. Little is known
about the impact of this important intervention on a broad range of other socio-economic
outcomes as well, both at the individual and household level.
In this paper, we use survey data from Kenya to present the first estimates of how quickly
and to what degree ARV therapy affects the labor supply of treated patients and their
household members. These estimates are a preliminary step in understanding the socio-
economic impacts of ARV therapy, which in turn is critical for properly evaluating
treatment programs and efficiently allocating resources. For example, if ARV therapy for
adult AIDS patients increases the likelihood that their children attend school, then such
impacts belong in any cost-benefit analysis. Of course, an assessment of the impacts of
treatment also provides valuable information about the impacts of the disease absent
treatment and as such our results could be viewed as a lower bound for the labor supply
declines due to HIV/AIDS as well. Estimates of these impacts can also contribute to the
growing literature on the long-term micro- and macroeconomic consequences of AIDS (e.g.
Bell, Devarajan, and Gersbach (2003) and Young (2005)).
Labor is the central productive asset of the poor in most developing countries. Indeed, labor
supply and related outcomes like income have been the focus of many studies that examine
the impacts of nutrition, morbidity, and AIDS-related mortality.4 Because it is an important
outcome, changes in the labor supply of adult AIDS patients can also generate
intrahousehold spillover effects on time allocation patterns and influence other measures of
household welfare.
Our analysis is based on data from a household survey we conducted in collaboration with a
rural treatment program in western Kenya. Over the course of one year, longitudinal socio-
economic data were collected from AIDS patients who receive free treatment. These data
have been linked to longitudinal medical data containing clinical and laboratory measures of
the patients’ health status. The presence of individuals whose HIV status is known, the ARV
treatment program, and the linked medical data combine to offer us a unique opportunity to
measure the effects of treatment.
To identify the response to treatment, we examine changes over time in the labor supply of
treated patients and their household members. Since ARV treatment eligibility is defined by
biological markers that are not easily influenced by the behavior of patients with late-stage
HIV disease, the provision of treatment at our study clinic and the resulting changes in
health are exogenous.5 Using data collected simultaneously from a large random sample of
non-patient households, we control for time-varying factors (such as seasonality) that could
bias the estimates. The analysis is strengthened by variation in the length of time that
patients had been exposed to treatment prior to the start of our survey. As we show with the
linked medical data, health has a non-linear temporal response to treatment—it improves
dramatically in the first months of treatment but more gradually thereafter. We exploit this
nonlinearity to test for heterogeneous treatment responses in the labor supply of patients.
We find that the provision of ARV therapy leads to a large and significant increase in the
labor supply of AIDS patients. This increase occurs very soon after the initiation of ARV
therapy: within six months, there is a 20 percent increase in the likelihood of participating in
the labor force and a 35 percent increase in hours worked – an impressive 7.9 hours – during
4Yamano and Jayne (2004) examine the impacts of working-age adult mortality on a range of household outcomes including crop and
non-farm income. Beegle (2005) examines the impacts of adult mortality on the labor supply of household members.
5Patients at the clinic where this study was conducted were not charged for laboratory tests and medicines, and treatment was
provided to all patients who required it on clinical grounds.
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the past week. Since AIDS patients left untreated will experience continued declines in
health and possibly death within six months, our estimated labor supply responses are
therefore underestimates of the impact of treatment on the treated. As such, we also
calculate an upper bound of the impact of treatment on the treated by assuming that patients
would be too sick to work (or even dead) without treatment. Clinical evidence on the
evolution of untreated HIV disease suggests that this is a reasonable assumption, and that the
upper bound estimate is close to the ‘true’ impact of treatment on the treated. This upper
bound is very large: over a period of six months, labor force participation for those initiating
therapy at the beginning of our survey increases by 85 percentage points and hours worked
increases by 26 hours per week relative to what would have happened if AIDS had
progressed untreated.
Given this effect on patients’ labor supply, treatment can also have spillover benefits within
the household. However, an analysis of how ARV therapy influences the labor supply of
treated patients’ household members is complicated, as the effects are theoretically
ambiguous. On the one hand, the increase in a patient’s labor supply has an income effect
that allows other household members to work less. On the other hand, the improvement in
the patient’s health reduces the care-taking and housework burden on family members,
thereby having a time endowment effect that allows for more work and leisure. We find that
the labor supply of younger boys in patients’ households declines after the initiation of ARV
therapy, suggesting that the income effect from the treated patients’ increased labor supply
dominates. In multiple-patient households, both younger and older boys, as well as other
adults in the household, work less after patients receive treatment. This suggests that
intrahousehold decisions about time allocation are influenced by the provision of treatment,
and that the welfare of some household members beyond the patient may increase
considerably as a result. The effects on the labor supply of younger children are particularly
important since they suggest, among other things, potential schooling impacts from
treatment, and the returns to primary school education are especially large in developing
countries.
This paper is organized as follows: in Section II, we provide a brief overview of the key
stages of HIV infection and the role of ARV therapy in treating infected individuals. We
then discuss our survey data in Section III. Section IV uses medical data from the HIV clinic
where this study was conducted to show that measurable dimensions of patient health
improve after initiation of treatment. We discuss our strategy for estimating the response in
treated patients’ labor supply in Section V and present the results in Section VI. In Section
VII, we examine the labor supply of children and adults living with ARV recipients. Section
VIII concludes and discusses the policy implications of this research.
II. Background on HIV/AIDS and Antiretroviral Therapy
The human immunodeficiency virus (HIV) affects the health of individuals and eventually
causes acquired immune deficiency syndrome (AIDS) because it destroys white blood cells
that are essential to the immune system. In sub-Saharan Africa, most HIV transmission
among adults occurs through sexual intercourse between men and women (UNAIDS 2006).
Soon after transmission, infected individuals enter a clinical latent period of many years
during which health status declines gradually and few symptoms are experienced. Median
time from seroconversion to AIDS in east Africa is estimated to be 9.4 years (Morgan et al.
2002).6 During this latency period, most HIV-positive individuals are unaware of their
status and physically capable of performing all normal activities.
Over time, almost all HIV-infected individuals will experience a weakening of the immune
system and progress to developing AIDS. This later stage is very often associated with
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substantial weight loss (wasting) and opportunistic infections such as P. carinii pneumonia,
Kaposi’s sarcoma, and tuberculosis. In resource-poor settings, absent treatment with ARV
therapy, death usually occurs rapidly after progression to AIDS. One study in Uganda
reports a median survival time of 9.2 months (Morgan et al. 2002) and another study in
Brazil reports a median survival time of 5.1 months (Chequer et al. 1992). These estimates
are not very different from those found for untreated populations in industrialized countries,
where the estimated survival times following clinical diagnosis of AIDS are about one year
(Lemp et al. 1990; Lee et al. 2001).
Highly active antiretroviral therapy7 has been proven to reduce the likelihood of
opportunistic infections and prolong the life of HIV-infected individuals. After several
months of treatment, patients are generally asymptomatic and have improved functional
capacity. As we discuss in Section IV, individuals are considered eligible for ARV therapy
after they progress to AIDS. Numerous studies in various countries and patient populations
have reported positive results.8 In Haiti, patients had weight gain and improved functional
capacity within one year after the initiation of ARVs (Koenig, Leandre, and Farmer 2004).
In Brazil, median survival time after developing AIDS rose to 58 months with ARV therapy
(Marins et al. 2003). Section IV documents similar health impacts for patients in our sample.
The price of ARV therapy in developing countries is an important issue in discussions about
treatment provision. First-line ARV regimens used to cost more than $10,000 per patient per
year. However, since 2000 widespread generic production of medicines has reduced these
prices significantly, to as low as $140 (negotiated by the Clinton Foundation for treatment in
selected countries) in 2004 (Gutierrez et al. 2004; Campaign for Access to Essential
Medicines 2005). Further declines may be possible with greater generic competition and
bulk purchasing agreements. Expenditures on lab tests and HIV clinic operations can also be
sizable, with the sum of these non-drug costs dependent on the treatment setting.
III. Sampling Strategy and Survey Data
The socio-economic data used in this paper come from a household survey we conducted in
Kosirai Division, a rural region near the town of Eldoret, in western Kenya.9 The Division
has an area of 76 square miles and a population of 35,383 individuals living in 6,643
households (Central Bureau of Statistics 1999). Households are scattered across more than
100 villages where crop farming and animal husbandry are the primary economic activities
and maize is the major crop.
The largest health care provider in the survey area is the Mosoriot Rural Health Training
Center, a government health center that offers primary care services. The health center also
contains a clinic that provides free medical care (including all relevant medical tests and
ARV therapy) to HIV-positive patients. This rural HIV clinic (one of the first in sub-Saharan
Africa) was opened in November 2001 by the Academic Model for the Prevention and
Treatment of HIV/AIDS (AMPATH).10 Following increased funding since late-2003, the
6Conversion to HIV-positive serology normally occurs 4–10 weeks after transmission. The duration of the clinical latent period has
been found to vary considerably, depending upon the mode of transmission and age at transmission (Collaborative Group on AIDS
Incubation and HIV Survival including the CASCADE EU Concerted Action 2000). In developing countries, limited access to health
care and greater burden of other infectious diseases may expedite the progression of HIV.
7In this paper, we use the terms “ARV therapy” and “ARV treatment” to refer to highly active antiretroviral therapy (HAART), which
was introduced in 1996. HAART always consists of three antiretroviral medications, with a common first-line regimen of nevirapine,
stavudine, and lamivudine. Generic medications that combine three medications in one pill (such as Triomune) have recently become
available.
8Since placebo-controlled randomized trials of ARV therapy are ethically infeasible, these studies are either observational cohort
studies or randomized trials that compare regimens composed of different antiretroviral medications.
9Kenya has an estimated 1.3 million HIV-infected individuals and an adult prevalence rate of 6.1 percent (UNAIDS 2006).
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Mosoriot HIV clinic has experienced rapid growth: the number of patients has risen from
about 150 in early-2003 to 2,149 in September 2005 (communication with AMPATH), with
many patients coming from outside Kosirai Division. During this period, adequate funding
has been available to provide free ARV therapy to all patients sick enough (according to
WHO treatment guidelines that are discussed in the next section) to require it.11
We implemented two rounds of a comprehensive socio-economic survey between March
2004 and February 2005, with an interval of roughly six months between rounds.12 The
survey sample contains two different groups of households. The first group comprises 503
households chosen randomly from a census of all households in Kosirai Division without an
AMPATH patient (random sample households).13 The second group comprises 200
households that were chosen at the clinic and contained at least one adult HIV-positive
AMPATH patient who began receiving ARV therapy (ARV households) prior to round 2.
The ARV sample is part of a larger sample of 260 households containing at least one HIV-
positive AMPATH patient (at various stages of HIV disease), all of whom were recruited at
the Mosoriot HIV clinic.14,15 All non-pregnant AMPATH patients who enrolled in the
Mosoriot HIV clinic before April 2004 and resided in Kosirai Division were considered
eligible for our survey since it would be possible for survey staff to visit these households at
home. To obtain a larger sample size, we also conducted in-clinic interviews with a random
sample of non-pregnant AMPATH patients who entered the clinic before April but resided
outside Kosirai Division and too far away from the clinic to be visited at home. Pregnant
women were excluded from the sample because treatment was typically given to these
women for the prevention of mother-to-child transmission of HIV, not because the women
had become sick enough to require ARV therapy.
Upon completion of the survey, we used the AMPATH Medical Records System (AMRS)—
which contains clinical and treatment-related information on all patients—to establish which
of the HIV-positive AMPATH patients in our sample were receiving ARV therapy. It was
established that out of the 260 households with AMPATH patients, there are 217 HIV-
positive adults (from 200 households) who began receiving ARV therapy at the Mosoriot
HIV clinic prior to the round 2 interview (we report the distribution of treatment start dates
in Section IV).16 Attrition of entire households between rounds due to refusal or relocation
is minimal in the random sample (seven out of 503 households), and attrition of individuals
10AMPATH is a collaboration between the Indiana University School of Medicine and the Moi University Faculty of Health Sciences
(Kenya). Descriptions of AMPATH’s work in western Kenya can be found in Mamlin et al. (2004), Cohen et al. (2004), and Einterz et
al. (2007).
11As of November 2005, ARV therapy was being provided to an estimated 55,000 out of 273,000 Kenyans needing treatment (WHO
2006). About 17 percent of the Kenyans receiving ARV therapy are patients at one of AMPATH’s urban and rural clinics (based on
AMPATH and Kenya statistics from June 2005).
12Round 1 was between March and August 2004. Round 2 was between September 2004 and February 2005. The last month in each
round contained the fewest interviews since they were mostly spent interviewing the respondents who were not found earlier in the
round. In the remaining months, the number of interviews was fairly uniform, with June and December somewhat less intensive (the
latter due to holidays at the end of the month).
13In the random sample, the HIV status of respondents is usually unknown, unless the respondent gives a self-report of having gone
for an HIV test and testing HIV-positive or HIV-negative.
14We include in this sample two adults (and their household members) who were originally part of the random sample but enrolled in
the AMPATH clinic and began receiving ARV therapy between rounds. As we discuss below, several other patients in the ARV
sample also initiated ARV therapy between rounds.
15The analysis in this paper excludes the 60 households with HIV-positive AMPATH patients who were in the early stages of HIV
disease and were not yet sick enough to require ARV therapy (according to WHO treatment guidelines). We exclude this group from
our analysis in this paper because these untreated HIV-positive patients would not have experienced significant health changes during
the survey period. The small sample size of these HIV households also limits our ability to use them as a control group in the data
analysis. All analysis in the paper is thus restricted to the 200 households with ARV recipients and households from the random
sample.
16HIV-positive children of adult patients were not interviewed. Included among the 217 adults are household members who were
reported by the respondent to be HIV-positive ARV recipients and for whom an AMPATH identification number was found in the
AMRS.
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due to mortality is also negligible (seven out of 3,009 individuals). We discuss attrition of
individuals for reasons such as marriage and employment in the next section. In the ARV
sample, a total of 22 patients attrite from the sample between rounds (ten due to mortality,
seven due to loss to follow-up17, and five due to relocation). In the analysis below, we
attempt to correct for bias that may be introduced by this attrition. Furthermore, information
on the key labor supply measures used as outcome variables is not available for four patients
in round two (because they were away from the household for an extended period). This
leaves a total sample of 191 adult ARV recipients who appear in both survey rounds.
The survey included questions about demographic characteristics, health, agriculture,
income and employment. In the household visits, teams of male and female enumerators
interviewed the household head and spouse as well as a youth in the household. For in-clinic
interviews, all information was obtained from the AMPATH patient. In total, 81 percent of
all survey households were visited at home. Height and weight measurements were made for
children under the age of five years. Relevant outcomes such as asset sales and purchases,
child anthropometrics, school enrollment and attendance, income, employment, and food
consumption were recorded in each round to obtain longitudinal data.
Table 1 provides an overview of the main characteristics of households in the random
sample and ARV sample during round 1. On average, households in the survey area have
6.04 members. ARV households tend to be significantly smaller, with 5.52 members on
average. There are also significant differences in the sex and marital status of household
heads and the orphan status of children: ARV households are more likely to be headed by a
woman who has lost her husband, whereas random sample households are generally headed
by a married man. ARV households also own significantly less land and livestock, which is
one of several indications from the survey that they are worse off than other households in
the community.18
IV. ARV Therapy and Patient Health
The AMPATH Medical Record System (AMRS) contains longitudinal information on the
health status of patients at AMPATH’s eight HIV clinics in western Kenya. Before
estimating how labor supply responds to ARV therapy, we discuss evidence from the AMRS
on the health response to treatment.
Since HIV enters and destroys T cells with the protein CD4 on their surface, the CD4+ T
cell count is an important indicator of disease progression among HIV-infected individuals.
19 HIV-infected individuals are considered to have developed AIDS when they have one of
several opportunistic infections or a CD4 count below 200/mm3. It is at this stage when
functional capacity deteriorates and, according to WHO guidelines (WHO 2002), patients
should be initiated on ARV therapy.20
The CD4 count of AMPATH patients is monitored at intervals of roughly six months.21 The
AMRS also contains more frequent measures of the body mass index (weight/height2, BMI),
a well-known indicator of short-term health for patients with AIDS (WHO 1995). Wools-
Kaloustian et al. (2006) have recently analyzed longitudinal data for all non-pregnant adult
17Loss-to-follow is the term used for patients who did not attend the clinic for several appointments and whose mortality status cannot
be established.
18For further details on the household survey and the first round data, see Goldstein et al. (2005).
19Most uninfected individuals have a CD4+ T cell count of 800 to 1000 per mm3 of blood.
20The WHO guidelines have been followed by many treatment programs in developing countries, including AMPATH. See Grubb,
Perriens, and Schwartlander (2003) and Mamlin et al. (2004).
21The CD4 count was obtained less frequently and at unspecified intervals prior to 2004, when funding was more limited. It is
important to note that CD4 counts during this period were conducted free-of-charge.
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patients treated with ARV therapy at AMPATH’s HIV clinics and found significant
increases in the CD4 count and weight following the initiation of treatment. Since the exact
timing of this health response among patients in our sample will be useful for motivating our
strategy for estimating and interpreting the labor supply response to treatment, we focus here
on the AMRS data from patients in our sample.
Figure 1, which shows the mean CD4 count in intervals of ten weeks before and after
initiation of treatment (baseline), reveals a pronounced temporal pattern in health status
improvements experienced by patients at the Mosoriot HIV clinic.22 The response of CD4
count is highly non-linear: at 10–20 weeks, the median CD4 count has risen to levels at
which patients are generally asymptomatic. Subsequent changes are smaller and less
consistent.23 A similar non-linear relationship is found for the BMI (not shown). As will be
shown in the next section, this health response pattern has important implications for our
identification strategy. The extremely low CD4 counts of patients at the time that treatment
is initiated are also noteworthy, as it is suggestive of extremely low life expectancies absent
treatment. We discuss the implications of this in subsequent sections.
Since patients do not have a CD4 count in every cell of Figure 1, the cross-sectional
relationship shown may differ from the average experience of individual patients. Thus,
restricting the analysis to all available post-treatment measures of CD4 count or BMI for the
adult ARV recipients in our survey, we estimate the following equation using patient fixed
effects:
(1)
αi is a patient fixed effect, Hit is a measure of patient i’s health status (CD4 count or BMI)
during the appointment at time t, and ARVi,t-τ indicates whether or not patient i was
receiving ARV therapy τ months prior to the appointment when health status is measured.
24,25 The omitted time period is the span of three months after initiation of treatment. Table
2 reports results from estimating equation 1 with CD4 and BMI as the dependent variables
(columns 1 and 2, respectively). The increase in CD4 count during the first three to six
months of ARV therapy is substantial (127/mm3) and statistically significant. After six
months of treatment, marginal increases are smaller. For BMI, which is measured more
frequently, we estimate a more continuous version of equation 1 with additional time
intervals. Here again, the largest increase occurs soon after initiation of treatment, but there
are also significant increases in subsequent months.
22Due to the low frequency at which CD4 count is measured, we chose a group size that is large enough to produce a relatively
smooth curve. When mean CD4 counts are calculated for intervals of less than ten weeks, the figure looks similar. Likewise, a similar
pattern is evident when median CD4 counts are calculated in each time interval.
23These figures do not correct for mortality bias, which will lead to an overestimate of trends in CD4 count and BMI. Since mortality
rates are low in the period immediately following treatment, the short-term trends should be relatively accurate. But mortality is more
of a concern for long-term trends. Since patients who die are generally those who presented with advanced disease and very low
baseline CD4 counts, the long-term trends displayed here will be more applicable to patients who begin treatment before becoming
very sick.
24Since there are very few patients with multiple measurements of CD4 counts during the pre-treatment period, it is not possible to
estimate the trajectory of CD4 count in this period with patient fixed effects. In cross-sectional regressions of CD4 count on weeks
before initiation of ARV therapy, however, there is a significant overall negative trend in CD4 count prior to initiation (as shown in
Figure 1).
25Following Wools-Kaloustian et al. (2006) and other studies, if a CD4 count is not available at the time ARV therapy is initiated, the
baseline CD4 count is taken to be nearest available CD4 count in the three months before or 15 days after the time of initiation.
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Finally, for the 191 adult ARV recipients in our sample who appear in both survey rounds,
Table 3 reports the number of days that they had been receiving ARV therapy relative to the
round 1 interview date. While the average number of days between round 1 and the
treatment initiation date is 172, we find substantial variation here: 19 percent had not yet
initiated ARVs at the time of the round 1 interview, and 26 percent had been on ARVs for
fewer than 100 days. Figure 2 shows the density of days on treatment as of the round 1
interview and further illustrates the variation within the sample of 191 ARV recipients.
Table 3 also summarizes the available data on CD4 counts and BMI at time of treatment
initiation, the round 1 interview, and the round 2 interview. The non-linear temporal
response of health status to ARV therapy (Figure 1) and the variation in treatment duration
as of round 1 (Table 2) illustrates that treated patients in our sample experienced varying
amounts of health improvement between the survey rounds. In the next section, we exploit
this variation to test for heterogeneous treatment responses in labor supply.
V. Estimation Strategy for Patients’ Labor Supply Response
We primarily study two outcomes that measure an individual’s labor supply: an indicator of
participation in any economic activities during the past week and the total number of hours
worked in the past week. For all household members older than eight years, the survey
recorded this information in each round for three types of activities: wage and salaried jobs,
farming on the household’s owned or rented land, and non-farm self-employed work. Our
measure of market labor supply is defined as the total hours devoted to all of these activities.
Information on labor supply of household members was typically provided by the household
head, except in the case of clinic interviews, during which the patient provided all
information about the household.26
The first indication that ARV therapy influences labor supply is provided by Figures 3 and
4, which combine data from the two survey rounds (for the ARV sample only) and plots the
relationship between adult ARV recipients’ labor supply outcomes and time on treatment.
The temporal pattern of labor force participation rates (Figure 3) and weekly hours worked
(Figure 4) closely resembles the non-linear response of medical outcomes. In this section,
we discuss the main estimation strategies used to test the hypothesis that ARV therapy
results in increased labor supply. Results from employing these strategies are presented in
the next section.
The motivation for our empirical work comes from the following labor supply function,
which is drawn from Strauss and Thomas (1998) and can be used to describe the relationship
between health and labor supply:
(2)
Labor supply (L) is affected by health (H) through two distinct channels: first, health can
influence an individual’s productivity or real wage (w), and second, independent of its effect
on wages, health can influence the marginal rate of substitution between consumption goods
and leisure (if we assume that health, consumption, and leisure are all directly valued by the
individual). A host of other factors will also influence labor supply, including the price of
consumption goods (pc), individual and family characteristics (X) such as education,
schooling, family background, and wealth, unexpected events (ew) such as weather shocks
that influence labor demand, as well as unobservables such as ability (α) and tastes (ξ).
26For household members who were away for an extended period, respondents were typically unable to provide information on hours
worked in the past week. These individuals are excluded from the data analysis, as we discuss in the next section.
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Estimating the total effect of health in a reduced form equation for labor supply is difficult
for well-known reasons that are discussed in the literature: bias from omitted variables (such
as ability) that are correlated with both wages and health, simultaneity problems that arise
from health and income influencing each other contemporaneously, and errors in the
common measures of health. Since we are interested in estimating the reduced form effect of
ARV treatment on labor supply, we overcome these problems by taking advantage of the
panel structure of our data and the exogenous health improvement that occurs due to the
provision of treatment. We now discuss the identification strategy and the reduced form
equations that we use to estimate the labor supply response to ARV treatment.27
We identify the response to ARV therapy by examining changes in the treatment group’s
labor supply between rounds. Since labor supply is also influenced by several time-varying
factors such as seasonality in agriculture (which influences local prices and labor demand)
and aggregate health shocks (a greater malaria burden in specific months, for example), we
include data from the random sample of adults to control for secular trends in the survey
area. Thus, our key identifying assumption here is that data from the random sample control
for the part of the ARV sample’s labor supply trends that are due to factors other than
treatment, such as seasonality. This strategy is similar to a difference-in-difference
estimation strategy in which the “comparison group” is the sample of adults from the
random sample.28 However, it should be noted that the labor supply trends in the random
sample do not represent the counterfactual scenario of no treatment, and as such the reduced
form empirical strategy we describe below estimates the treatment effect relative to baseline
levels, but does not estimate the average treatment effect on the treated (the latter is
discussed in Section VI.D). More formally, the reduced-form treatment response is
identified by estimating individual fixed effects regressions in which a time interaction for
ARV recipients measures the change in their labor supply between survey rounds:
(3)
Lit is the labor supply outcome of interest for individual i in time t (round 1 or 2), αi is a
fixed effect for individual i that captures the effects of time-invariant variables like
demographic characteristics, schooling, family background, as well as unobservables such as
ability and tastes, ARVi is an indicator variable equal to one if individual i is an ARV
recipient, and ROUND2t indicates whether the observation is from round 2.29 The round 2
indicator and ten month-of-interview indicator variables (with one month from each round
omitted to avoid singularity) together control for monthly fluctuations in labor supply in the
27In an earlier version of the paper (Thirumurthy, Graff Zivin, and Goldstein 2005), we also estimated labor supply regressions in
which the length of time on ARV therapy was used as an instrument for health status (measured by the CD4 count or body mass
index). This instrumental variables (IV) approach, which estimates the relationship between health and labor supply, confirms that the
reduced-form results obtained in this paper are largely driven by the health improvements associated with ARV therapy. We pursue
the reduced-form estimation strategy here, as it more closely resembles the policy experiment that most people have in mind when
debating the merits of providing ARV therapy to people with AIDS in Africa.
28This also resembles the estimation strategy used by Jacobson, LaLonde, and Sullivan (1993). The authors use a longitudinal dataset
to estimate the temporal pattern in earnings losses of displaced workers. In their estimation strategy, one reason why nondisplaced
workers are used as a comparison group to displaced workers is that it is important to control for macroeconomic factors that can
cause changes in workers’ earnings.
29This equation could also be approximated without individual fixed effects as:
(3′)
in which the level is assumed to vary systematically by ARV status.
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entire community.30 The coefficient of interest, β1, measures the average change in labor
supply between rounds due to the provision of ARV therapy.
The specification in equation 3 is designed to capture the average labor supply response to
treatment between survey rounds for all ARV recipients in the sample. However, as noted
earlier, patients have been on treatment for varying lengths of time during our round 1
interviews and the largest health improvement occurs during the first three months of
treatment. We would therefore expect the largest labor supply changes between rounds to
occur for patients in the early stages of treatment (assuming labor supply responds to health
changes with only a short lag). Since the size of our ARV sample does not provide us with
enough statistical power to estimate heterogeneous treatment responses using time on
treatment in round 1 as a continuous variable, we employ a more parsimonious specification.
We estimate a specification in which ARV recipients who were yet to begin treatment in
round 1 or had been on ARVs for less than 100 days in round 1 (represented by )
can experience a different change in labor supply between survey rounds than ARV
recipients who had been on ARVs for more than 100 days in round 1 ( ). This
distinction divides the ARV sample into two roughly equal samples, and distinguishes
between patients experiencing large and small health improvements.31 The following
modified version of equation 3 is thus estimated:
(4)
Equation 4 allows us to take advantage of variation in the amount of health improvement
experienced by patients to establish whether there is a temporal pattern in the labor supply
response to ARV treatment.32 While the primary identification strategy in equation 4
remains similar to equation 3 in that we use longitudinal data for the two treatment groups
and correct for secular patterns in labor supply with data from the random sample, the
interpretation of β1 and β2 as indicating the temporal pattern in the treatment effect relies on
the assumption that the only important difference between these two groups is the time they
have been “exposed” to ARV treatment. Of particular concern is the scenario under which
30If the labor market impacts from ARV therapy were large enough to influence market wages (or local agricultural output prices),
the random sample will also control for such aggregate effects. On the other hand, to the extent that certain aggregate health shocks
disproportionately affect HIV-positive individuals such as the ARV recipients, data from the random sample alone will not adequately
control for the labor supply effects of such shocks.
31The round 1 labor supply for patients in the ARV<100 group can be thought of as approximating their baseline (time of treatment
initiation) labor supply. Some individuals in this group began treatment before the Round 1 interview and may have experienced some
improvements in health and labor supply before our initial interview, Others will be about to begin treatment and would have health
status and labor supply that is higher than on the day of treatment initiation. For such individuals, the approach in equation 4 will
likely underestimate the impact of treatment. For patients in the ARV>100 group, the round 1 information represents their labor supply
at a point in time that is well removed from the baseline date.
32Since 19 percent of the ARV recipients in our sample began treatment between rounds 1 and 2 (with nearly all of them beginning
treatment within two months after round 1), it is possible to estimate treatment effects by exploiting within-person variation in
treatment status during rounds 1 and 2 (that is, by including a stand-alone dummy variable ARVit in equation 3). Given the
concentration of health benefits within the first six months of treatment, we estimate heterogeneous treatment effects in equation 4
without including the dummy variable and instead treat individuals who are “close” to the start of treatment in round 1 as one group.
As we note in Section 6, the results are robust to the inclusion of ARVit in equations 3 and 4. We do not divide this group into two
groups (0–100 days as of round 1 and yet to start treatment as of round 1) because it also limits our statistical power to test for the
impact of treatment when we examine sub-groups of male and female patients.
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those patients who began treatment long before round 1 are better informed or better
connected than those who began treatment shortly before round 1. This does not appear to
be the case, as the AMPATH medical records reveal no significant differences in the health
status of patients in the two groups (as revealed by the CD4 count) at the time of treatment
initiation. We also find no significant differences in other important characteristics of
patients in the two groups. Both are indistinguishable with respect to education, household
size and demographic characteristics, distance to clinic, and wealth measures such as land
and livestock holdings.33
While the division of ARV recipients into two samples will indicate whether there are
heterogeneous responses during the post-treatment period, the use of 100 days as a cutoff for
determining long and short duration of ARV therapy can be seen as arbitrary.34 To trace the
response of labor supply more carefully, we construct indicators of whether or not the
patient has been receiving ARVs for incremental durations of three months. The random
sample is again used as a “comparison” group in this analysis to control for seasonality.
Specifically, the following equation is estimated:
(5)
ARVi,t-τ indicates whether or not individual i was receiving ARVs τ months prior to the
interview at time t (round 1 or round 2). In this specification, the outcomes of patients are
compared at different times in the post-treatment period, with the period of three months
before and after treatment initiation serving as the omitted time period.35 Due to the
relatively small number of patients in our sample who have been on treatment for more than
18 months, we do not add an additional term to capture the marginal effect of treatment
during the post-18 month period, but instead allow it to be captured by the coefficient for the
ARVi,t−5 term. Data from adults in the random sample again control for secular trends in the
labor market.
The individual fixed effects in all of the equations estimated will allow for ARV recipients
to have different levels of labor supply than other adults in the sample. While time varying
factors such as seasonality are dealt with using the time indicators, the key assumption in
identifying the treatment response is that the ARV recipients in the sample do not have
characteristics that influence the change in labor supply between rounds. The only form of
heterogeneity in the treatment response allowed by the equations above is in the temporal
pattern of the response. In the analysis below, however, we also test for heterogeneity in the
treatment response according to the gender of the ARV recipient.
33For each of these observed characteristics, we conducted t-tests and were unable to reject the hypothesis that the means for the two
groups of ARV recipients are equal.
34While the specific choice of 100 days is arbitrary, the results obtained from estimating equation 5 suggest a rather narrow range of
candidate cutoff values. In unreported analyses, we have also estimated our primary specification (equation 4) using cutoffs ranging
from 90 – 110 days and our results remain unchanged.
35Note that the definition of the indicator variables implies that the coefficients are marginal effects of completing additional months
of ARV therapy. That is, patients who have completed 6–9 months of ARV therapy will experience an average increase in labor
supply (relative to the three months before and after initiation) that is equal to β2+β3. Also, the term ARVt+3 is included to estimate
differences in labor supply in periods that are more than three months before the initiation of treatment.
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VI. Results for Adult Patients’ Labor Supply Response
We restrict the analysis of labor supply to individuals between the ages of 18 and 65 who
appear in both rounds.36 Table 4 presents summary statistics from the first round for 191
adult ARV recipients and 1,286 adults in the random sample.37 Crop farming is the primary
economic activity of households in the survey area, as 84 percent of the random sample
adults and 60 percent of adult ARV recipients reported having worked on their farm in the
past seven days. A non-trivial fraction of adults also report working off-farm for a wage
(17–18 percent) or in a household enterprise (16–17 percent).
Table 4 shows that in the first round, ARV recipients are significantly more likely to not
have done any work in the past week (24 percent of ARV recipients compared to 11 percent
of adults in the random sample). ARV recipients also work significantly fewer hours than
other adults, unconditional on participating in the labor force (24 hours compared to 35
hours) and conditional on participating (32 hours compared to 40 hours). Table 5
summarizes the respondents’ reported reasons for not having worked in the past week. Only
eight percent of unemployed adults in the random sample report being sick as the reason for
not having worked. In contrast, being sick is the reported reason for 85 percent of
unemployed adult ARV recipients. It is also interesting to note that the percentage of all
random sample individuals not working for reasons other than illness is more than twice the
figure for all ARV patients.
The data also show the importance of controlling for seasonal variations in labor supply.
Figure 5 plots the average weekly hours worked in each month of the survey. There is a
peak during the maize planting and harvesting seasons—the months of April and May (in
round 1) and November through January (in round 2), respectively.38 Because of the
seasonality in agriculture and the reliance of most people on self-employed farming, for the
most part we do not focus on outcomes such as income or wages.39 Instead, most of our
analysis below examines individuals’ labor force participation and hours worked.
A. Individual Fixed Effects Results
To identify the impacts of ARV treatment between the two survey rounds, we estimate labor
supply regressions with individual fixed effects, as discussed in Section V. Table 6 reports
results from estimating equations 3 and 4. We find that ARV therapy leads to a large and
statistically significant increase in labor supply. Adults receiving treatment are 8.5
percentage points more likely to participate in the labor force in round 2 than in round 1
(column 1), controlling for time-varying factors that are evident in both the ARV sample and
36Adults who move into the household between rounds are thus excluded. Also, we exclude 115 adults who migrate out of the
household permanently before round 2 or who live in households that were not found in round 2 (this includes the ARV recipients
who were lost-to-follow-up by AMPATH). Finally, 43 adults are excluded because the respondent for the labor supply questionnaire
did not know, in at least one round, how many hours the adult worked in the past week (possibly because the person migrated
temporarily). Rates of absence from round 2 due to reasons other than mortality do not differ significantly for ARV recipients and
adults in the random sample. Even when we control for age, sex, and education, ARV recipients are not significantly more likely to be
absent during the second round. The role of attrition due to mortality is discussed in Section VI.C.
37Household members of the ARV recipients are not included in any of this analysis. To the extent that labor supply of these adult
household members is affected by the changing health status of the ARV recipient, pooling them with adults in the random sample
may produce biased results.
38The month of August appears as an exception, but this is likely due to the fact that relatively few individuals were interviewed
during that month (when round 1 was concluding). The median for this month is considerably lower, at 38 hours.
39Due to the seasonality of agriculture, income tends to be concentrated after harvest periods. We find that household income shows a
sharp peak during December and January, when most households sell maize after the annual harvest (not reported). It is therefore not
very meaningful to compare changes in income between rounds. Furthermore, agricultural income is often only attributed to the
household head (and more rarely, the spouse), even if multiple persons in the household work on the farm or contribute to a family
business. Since treated patients are not always the household head or spouse, the income reported for that person is not always a good
indication of the person’s productivity nor is it highly correlated with their hours worked. Therefore, it is not surprising that income
differences in Table 4 between ARV recipients and all other adults are not statistically significant.
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the random sample. Hours worked in the past week also increases significantly between
survey rounds, by 4.6 hours (column 2). Relative to the levels in round 1, this implies a large
increase in labor supply for the entire sample of ARV patients: labor force participation rates
rise by almost 11 percent, and weekly hours worked rise by 19 percent.
Columns 3 and 4 of Table 6 show a stronger and even more striking result. The individuals
with by far the largest increase in labor supply between the two rounds are patients who
began receiving ARVs less than 100 days prior to the round 1 interview (a group that
includes some individuals who began receiving ARV therapy shortly after round 1). The
magnitude of these increases is substantial: over the course of six months, patients who have
just initiated ARV therapy show a 17 percentage point increase in labor force participation
rates and a 7.9 hour increase in hours worked.40 Given round 1 labor supply levels of 65.1
percent and 20.3 hours for this group, the estimates imply a 26 percent increase in
participation rates and a 39 percent increase in hours worked. In contrast, the other ARV
recipients in our sample show no statistically significant change in outcomes between
rounds.41 This temporal pattern in the labor supply response among treated patients very
closely resembles the health responses (in BMI and CD4 count) reported in Section IV.
Since the regressions of hours worked includes individuals not participating in the labor
force during round 1, the results do not clearly establish whether the labor supply response is
also applicable to patients already working in round 1. In column 5 of Table 6, we present
results for a restricted sample that includes only those adults who were participating in the
labor force during round 1. Since we do not find a statistically significant effect on hours
worked, the results suggest that the main treatment response occurs on the extensive margin
of labor supply--allowing patients who were previously too sick and incapable of working to
enter the labor force.
The results for ARV patients who have just initiated treatment are noteworthy since these
patients are particularly sick before starting treatment and at the time of the round 1
interview. As discussed earlier, in the absence of treatment these patients have a small
probability of living for another six months, until the round 2 interview date. In this sense,
the estimated labor supply responses are likely to be underestimates of the impact of
treatment on the treated.42
Table 7 reports the results from estimating equation 5, with a more complete set of
indicators to identify the temporal response to treatment. As columns 1 and 2 show, the
increase in labor supply is largest during the first three to six months of ARV therapy, with
subsequent increases being smaller and statistically insignificant. The point estimates show
that after three to six months on treatment, there is a 12.4 percentage point increase in labor
force participation rates (but not statistically significant at the ten percent level) and a
statistically significant increase of 7.3 hours in weekly hours worked. Compared to levels of
labor supply for patients who are within three months before or after initiation of ARV
therapy (the omitted group), this implies a 20 percent increase in the labor force
participation rate and a 37 percent increase in hours worked.43
40When we allow patients on treatment for 0–100 days in round 1 to have a separate change in labor supply than patients who begin
treatment between rounds 1 and 2 (the treatment effect for the latter group being estimated by adding at ARVit term to equation 4), we
find that both groups have identical and significant changes in labor force participation rates and that patients who begin treatment
after round 1 have a slightly larger increase in hours worked.
41Comparisons of socio-economic characteristics of the two groups of ARV recipients show that there are no statistically significant
differences in the gender, education, and household characteristics such as household size and ownership of land and livestock (results
not reported). This implies that such characteristics cannot explain the large difference in the labor supply changes of the two groups.
42Because HIV/AIDS is a chronic disease where the health of AIDS patients (those in the later stages of the disease) steadily declines
in the absence of treatment, the typical problem of mean reversion in the outcome variable (Ashenfelter and Card 1985) does not apply
here and therefore does not bias the estimates.
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B. Decomposition of the Impact of ARV Therapy
The composition of adults’ economic activities exhibits considerable variation according to
gender and seasons of the year. Moreover, households with ARV patients are less likely to
be engaged in farming for reasons that may have to do with their past health history and
lower landholdings. In light of such differences, this section examines changes in labor
supply more carefully, focusing on the composition of economic activities and differences
between men and women.
Composition of Activities—Instead of using an aggregate measure of labor supply, we
estimate equation 4 separately for each of the three different types of labor supply that were
recorded in the survey: wage labor, farm labor, non-farm business labor. Data from adults in
the random sample are used to control for seasonal patterns in each of the labor activities.
The results in columns 1–3 of Table 8 indicate that much of the increase in labor supply
occurs in non-farm business work. Patients are more likely to begin doing wage labor and
farm labor as well, but these increases are not statistically significant. All of these increases
appear to occur among patients who are in the early stages of treatment in round 1. The
absence of a significant increase in farm work (which arguably requires the most physical
labor) is noteworthy and seems to suggest that ARV therapy does not restore the ability of
patients to do physical labor. However, when we limit our analysis to households that own
three or more acres of land, ARV recipients are found to experience a significant increase in
the likelihood of having done own-farm work and in hours worked on the farm. Thus, the
lack of an aggregate treatment effect on farm work appears to be driven by the presence of
ARV households with small landholdings.
The results for monthly income from each of the three labor activities (columns 4–6 in Table
8) underscore the significance of seasonality in interpreting income patterns. While farm
income is known to be highly seasonal, non-farm business income is less variable during the
year. As a result, business income should be more responsive to short-term changes in health
status. Indeed, we find there is a statistically significant increase in non-farm business
income for ARV recipients in the early stages of treatment (column 6 in Table 8).
Labor Supply Impacts by Gender—The survey data from each round show that men
are more likely to be engaged in labor market activities in the past week than women. In
results not reported, we also find gender differences for some components of labor supply:
women are much less likely to work for a wage, but equally likely to work in a non-farm
business. Thus it is possible that the impacts of ARV therapy on labor supply will differ
according to the gender of the patient and the comparison group used. To test for such
differences, we estimate equation 4 separately for men and women.
As columns 1 and 2 of Table 9 show, for male patients in the early stages of treatment, there
is no significant increase in labor force participation rates but a large and significant increase
of 12.7 hours in weekly labor supply between rounds (a 43 percent increase relative to their
average weekly hours worked in round 1). This suggests that among male patients, those
already working prior to initiation of treatment are the ones who increase their labor supply
after treatment. For women in the early stages of treatment, there is a large and significant
increase of 21.8 percentage points in the labor force participation rate between rounds (a 35
percent increase relative to their average participation rate in round 1), but no significant
increase in weekly hours worked. Combining these results with round 1 observations
provides an intuitive explanation for this pattern. Since men have high levels of participation
43For adult ARV recipients in our sample who have been on ARV therapy for fewer than three months, the labor force participation
rate is 61.56 percent and the average weekly hours worked is 19.68.
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to begin with, most of their response to improved health takes the form of additional hours
worked. For women, initial participation is low, so labor supply is the natural margin for
change.
C. Controlling for Attrition in the ARV Sample
Since our analysis so far has excluded ARV recipients who do not appear in our sample for
both rounds, the estimated labor supply responses apply only to those ARV patients who
survived and continued to come to the clinic until round 2. The average response to ARV
therapy for all treated patients is therefore likely to be smaller.
In the ARV sample, mortality of patients and loss to follow-up are the main reasons for
attrition of individuals (and households) between the two rounds of the survey. For patients
who were interviewed at the HIV clinic in round 1 but subsequently died or were lost to
follow-up, we were unable to obtain any household information in round 2. Patients who are
lost to follow-up can be assumed to have either stopped seeking HIV care altogether,
transferred to another clinic, or died (these patients have an average CD4 count of 79 at the
time of the round 1 interview). Of the 217 adult ARV recipients in our sample from round 1,
ten patients are known to have died before round 2, and another seven patients were not
found in round 2 (due to loss to follow-up).
A conservative approach to estimating the average labor supply response to ARV therapy is
to analyze the panel data while treating these attrited patients as individuals with zero labor
supply in round 2. Since it is unlikely that all patients lost-to-follow-up are dead or not
working in the labor market, this strategy provides us with a lower bound on the labor
supply response.44 As Table 10 shows, we find that even with the inclusion of zero labor
supply for patients who are deceased or lost to follow-up (columns 3 and 4), there is a large
and statistically significant increase in labor supply. All patients who had been on ARVs for
fewer than 100 days in round 1 experienced an 11.1 percentage point increase in labor force
participation rates and a 6.7 hour increase in weekly hours worked (compared to 17.0
percentage points and 7.9 hours in Table 6, for the analysis without attrited patients). In
regressions not reported here, we also use our rich dataset of observable characteristics to
model the attrition of individuals and then re-weight the sample using the inverse probability
weights (IPW) technique described in Fitzgerald, Gottschalk and Moffitt (1998) and
Wooldridge (2002).45 Our main results reported in Section VI.A are robust to the use of
these estimation strategies.
The reduced effectiveness of ARV therapy when it is initiated in very sick patients has been
widely reported in the literature (Hogg et al. 2001; Wools-Kaloustian et al. 2006). Rates of
progression to death are considerably higher when baseline CD4 counts are below 100/mm3,
thus compromising the short-term effectiveness of ARV therapy. In fact, for the nine
patients in our sample who died between round 1 and 2 and for whom a baseline CD4 count
can be obtained in the AMRS, the average baseline CD4 count was 35.5/mm3 (and the
average round 1 CD4 count was 53/mm3). This influences how to interpret the role of
mortality in our analysis. While our earlier results should be recognized as being valid only
for patients who survive, the broader relevance of these results is heightened if HIV-positive
patients begin receiving treatment before having advanced to late stages of the disease (as
44Attrited patients who have not died may be receiving care at other clinics. Alternatively, patients from far away may have missed
several appointments and therefore not been included in the round 2 sample.
45Specifically, this is done by using observed characteristics in round 1 including gender, age, education, marital status and health
measures (such as CD4 count) to predict the probability that a person is observed for the second time in round 2. The inverse of the
predicted probabilty then serves as the weight given to an observation in the labor supply regressions.
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will be the case when ARV treatment programs are scaled-up and become more
established).
D. Estimating the Impact of Treatment on the Treated
As noted earlier, there is strong evidence that the health of individuals who have developed
AIDS will decline rapidly without treatment, generally leading to death in less than one year
(Morgan et al. 2002; Chequer et al. 1992). Since the baseline CD4 counts of patients in our
sample are well below 200/mm3 (the level associated with developing AIDS), very few of
the patients would be working (or even alive) in round 2 without treatment. While this
counterfactual case is not observed by us, we can provide an upper bound of the impact of
treatment on the treated by assuming that without treatment, all patients in the sample would
not be participating in the labor force in round 2. While the ‘true’ impact of treatment lies
somewhere between our earlier estimates and the upper bound figures presented in this
section, the clinical evidence on disease progression suggests that the true impact will be
only slightly below the upper bound. Comparing the observed treated group to this
constructed control group, we can obtain difference-in-difference estimates of the treatment
impact. For patients who are just beginning treatment in round 1, the impact of ARV therapy
on labor supply is very large: an increase in the labor force participation rate of 85.4
percentage points, and an increase in hours worked of 26 hours (not reported). This
represents a 5-fold increase in participation and a 4-fold increase in hours worked relative to
our earlier estimates of the labor supply response to treatment (in Table 6). Moreover, this
suggests that our earlier results are considerable underestimates of the true impact of
treatment on the treated. While our earlier results are useful in understanding how labor
supply responds to health improvements among previously sick AIDS patients, the fact that
they are underestimates of the treatment impact should be borne in mind when evaluating
treatment interventions. In the concluding section of the paper, we use this estimated impact
of treatment on the treated to provide a rough comparison of the costs and benefits of ARV
therapy.
VII. Response of Family Labor Supply to ARV Therapy
Intrahousehold reallocation of time is known to be an important consumption smoothing
mechanism of households in low-income countries. In settings with imperfect financial
markets, households often adjust the time spent by children and adults in activities such as
schooling, housework, and employment in response to sudden changes in income and health.
These adjustments can have differential effects according to the age and gender of
household members. For example, Jacoby and Skoufias (1997) find that children’s school
attendance in rural India is responsive to seasonal fluctuations in income. Similarly, Chetty
and Looney (2007) show that unemployment shocks in Indonesia lead to large decreases in
households’ consumption levels and expenditures on children’s education. In the context of
our study, sudden changes in the income of adults (for better or worse, as would be the case
with and without treatment, respectively) can therefore have long-lasting welfare
consequences if children’s time allocation to schooling is affected. Other studies have
examined time allocation to household activities and labor market activities in response to
income and health shocks, finding that responses depend on the gender of household
members (Pitt and Rosenzweig 1990; Kochar 1995). Such evidence from developing
countries suggests that ARV therapy can also influence the labor supply of patients’ family
members. Having estimated a large increase in patients’ labor supply due to ARV therapy
(own-effect of health), this section examines the labor supply of children and adults in the
patients’ households (cross-effects of health).
There is a large theoretical and empirical literature on the role of income and substitution
effects in individual time allocation decisions (beginning with Becker 1965) and family
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labor supply (beginning with Ashenfelter and Heckman 1974). A simple model of family
labor supply can be used to illustrate the role of ARV therapy in influencing labor supply
within the family. Two effects are likely to be especially relevant. First, as the treated patient
begins to work, there is an income effect for the family. Since leisure is a normal good, the
cross-income effect within the family is negative and the increase in patient income leads
other household members to work less. Second, as the treated patient’s health improves, the
time demanded for taking care of the patient and performing additional housework is
diminished, thereby expanding other household members’ time endowment for work and
leisure. Since this “reduced caregiving” or “time release” effect exerts a positive influence
on the labor supply of the patients’ family members, the net effect of treatment on family
members’ labor supply is theoretically ambiguous. There is also a third, cross-substitution
effect on family members’ labor supply (in response to an income-compensated change in
the patient’s market productivity), which further complicates the household response. In the
standard model of family labor supply, this effect can be positive or negative depending on
whether the nonmarket times of the treated patient and the other family member are
complements or substitutes, respectively.
To estimate the net effect of treatment on child and adult labor in ARV households, we
examine longitudinal data on the labor supply of non-patient individuals in these households
and use data from random sample households to control for monthly fluctuations in labor
supply. Specifically, the following equation is estimated with longitudinal data for non-
patient individuals in ARV households and others in the random sample:
(6)
Liht is the labor supply measure of interest for individual i in household h at time t (round 1
or 2), αi is a fixed effect for individual i, ROUND2t indicates whether the observation is
from round 2, and ARVHH<100,h and ARVHH>100,h are indicator variables equal to one if
household h has an adult who was receiving ARV therapy for less than or more than 100
days, respectively, at the time of the round 1 interview. We estimate equation 6 separately
for men, women, and young and old boys and girls.
Table 11 presents summary statistics from the first round for children and adults in ARV
households and random sample households (excluding HIV-positive patients at the Mosoriot
HIV clinic). A large fraction of boys and girls in the random sample had engaged in some
labor market activities during the past week (78 percent and 74 percent, respectively),
although the mean number of hours is considerably lower than for adults.46 In general,
household members of ARV patients are equally or less likely to be working than others in
the random sample, although the cross-sectional comparisons can be misleading given
differences in wealth, education, and other characteristics between the two groups of
households.
46The mean hours worked by children are low enough to be consistent with regular school attendance, which will be examined in
subsequent work.
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Table 12 contains results from estimating equation 6. Panel A reports results for the labor
supply of men and women. As column 1 shows, soon after initiation of ARV treatment for
adult patients, there is a negative but insignificant change in the labor force participation
rates of adults in the patients’ households. For women in these households, the decline in
labor supply is greater—15.0 percentage points—and almost significant at the ten percent
level (column 3). This suggests that, at the margin, women are more likely to compensate
for changes in the AIDS patients’ labor supply by entering and exiting the labor force. As
men are generally more likely to remain in the labor force at all times, we do not observe
any significant adjustment of their labor force participation decisions (column 2).
Panels B and C of Table 12 contain results for the labor supply of boys and girls,
respectively. We examine responses among young and old children (8–12 years and 12–18
years) separately to capture potentially heterogeneous responses among them. The results
indicate that there is a large decline in the labor supply of young boys after an adult
household member begins to receive ARV therapy, but no significant change for older boys.
Girls do not significantly change their labor supply, regardless of age. Column 2 of the Panel
B shows that the decline in labor supply for younger boys in ARV households occurs
gradually. In households with an adult who began receiving treatment shortly before round
1, the decline in labor force participation rates of young boys is 14.6 percentage points but
not statistically significant. However, in households with adults who began receiving
treatment more than 100 days before round 1, labor force participation rates decline by 21.5
percentage points and this coefficient is statistically significant. Hours worked also declines
significantly for younger boys, with a reduction of 8.5 hours in households exposed to
treatment for more than 100 days at the time of round 1. Given that boys in ARV households
have an average labor force participation rate of 74 percent and average weekly hours
worked of 12.3 hours in round 1, the estimates in Table 12 imply extremely large declines in
labor supply between round 1 and round 2.47
All else equal, young children in Kenya are less likely to be engaged in economic activities
since there are no official school fees for primary school and the productivity of young
children is likely to be low. Older boys, on the other hand, are considerably more likely to
be engaged in economic activities and less likely to be enrolled in school (Central Bureau of
Statistics 2004; Beegle 2005). This may explain why, at the margin, young boys are more
likely to be pulled into the labor force when adults become very sick and then pulled out of
the labor force when the adults become healthy.48 Given that girls allocate fewer hours to
labor market activities and more hours to housework, ARV therapy is more likely to exert its
influence on their time allocation in the domain of housework (not measured in labor
supply), especially since adult women in the household appear to be adjusting their labor
supply in response to disease and treatment.
Another way of examining the influence of ARV therapy on household members’ labor
supply is to take advantage of variation in the number of treated adults in ARV households.
In nine percent of the ARV households, there are two adult patients receiving ARV therapy.
These households are much more heavily burdened by AIDS in the months prior to round 1
and experience larger health improvements between rounds than households with only one
ARV patient. Thus, we examine whether there are larger changes in labor supply in these
ARV household by estimating the following equation:
47Given strong divisions of labor along gender lines in our survey region, we might also expect the effect of treatment to depend on
the gender of both the treated patient and the child of interest. Unfortunately, since nearly 75 percent of adult ARV recipients in our
sample are women, there is not enough statistical power to examine such effects.
48Future research will examine whether there are corresponding changes in school enrollment or attendance for boys.
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The indicator variable ARVHH2patient,h equals one if household h has more than one adult
ARV recipient and zero otherwise. Likewise, ARVHH1patient,h equals one if household h has
only one adult ARV recipient.
The results from estimating equation 7 are presented in Table 13. In panel A, we find that in
double-patient households there are large and statistically significant declines over time in
the number of hours worked in the past week by both men and women. In single-patient
households, however, hours worked by adults do not change significantly. Panel B shows
that for boys of all ages, there is a much larger decline in labor supply in the double-patient
households than the single-patient households (columns 1 and 2). For young boys in double-
patient households, the decline in labor force participation is 75.6 percentage points, as
compared to 13.2 percentage points in single-patient households (column 2). Hours worked
by young boys in all ARV households also declines significantly, and the responses are
again larger in double-patient households (column 5). For older boys in double-patient
households, there is a significant decline in both labor force participation and hours worked
(columns 3 and 6). Older boys in single-patient households, however, do not experience any
significant change in labor supply. Finally, Panel C shows that the labor supply of girls does
not change significantly in both types of households.
These results suggest that in households with multiple adults who have developed AIDS,
other household members (particularly boys and adults) are forced to do considerably more
market work before treatment is initiated, possibly in the place of the patient. Upon initiation
of treatment, these household members are able to work less. More generally, in contrast to
the large positive changes in the labor supply of treated patients, the results in this section
always show zero or negative changes in the labor supply of patients’ household members.
These results suggest that the income effect from the higher labor supply of treated patients
is larger than the time release effect that comes from the treated patient no longer being sick,
thus allowing some household members to decrease their labor supply. They also suggest
that households are engaged in their customary function of smoothing total market and non-
market labor supply over time as they face the negative health shock of AIDS and the
offsetting, positive health shock from ARV therapy. An important implication of these
results is that ARV therapy influences outcomes of not just the treated patient but also
individuals living with the patient.
VIII. Conclusion
This paper provides the first evidence on how ARV therapy affects the labor supply of AIDS
patients and their household members. Using data from our household survey, we find that
patients have significantly higher labor supply within six months after the initiation of
treatment. This response is also large, with patients showing a 20 percent increase in labor
force participation rates and a 35 percent increase in hours worked. We also find that the
treatment effects for female patients are primarily on the extensive margin (participation),
while male patients primarily experience changes in the intensive margin of labor supply
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(hours). Importantly, these results suggest that with treatment, the labor supply of AIDS
patients can recover rapidly from periods of severe illness. We also find evidence that the
labor supply of patients’ family members (particularly young boys) declines after initiation
of treatment. This suggests that family members may have been compensating for
previously sick patients’ diminished labor supply and that they too experience some of the
benefits from treatment. These effects are larger and impact more household members in
multiple-patient families. Taken together, the results providence evidence that ARV therapy
has significant non-health benefits and influences a range of intrahousehold decisions.
In the absence of data from a randomly chosen sample of AIDS patients who do not receive
ARV therapy, it will be difficult to estimate the full impact of treatment on the treated.
Given ethical constraints to implementing such an evaluation, our strategy represents the
best available method of estimating the response to treatment while controlling for important
confounding factors (such as seasonality in labor supply). Moreover, especially for the case
of patients’ labor supply, we argue that our results are underestimates of the treatment effect
because there is considerable medical evidence that untreated AIDS patients will die very
quickly. Our conclusion that treatment results in significantly higher labor supply would
only be strengthened if the analysis were based on comparison to a true counterfactual
group.
Although the number of HIV-positive individuals requiring ARV therapy will continue to
grow during the next decade, treatment programs have yet to be scaled up in many countries.
The results presented in this paper are therefore highly relevant for evaluating such
interventions. In fact, the labor supply response we have estimated can provide an important
first step in analyzing the costs and benefits of ARV therapy. Median daily wage rates for all
adults doing casual wage labor in our sample are 100 Kenya shillings, or about $1.50. Since
this daily wage is associated with six hours of work, the hourly wage is about 17 Kenya
shillings, or $0.25. Using our base case estimates of a 6.9 hour average increase in weekly
hours worked, treatment can thus be expected to yield an average wage benefit to patients of
$86 per year (assuming individuals work 50 weeks per year). This estimate is based on the
labor supply impact relative to pre-treatment labor supply. However, for the purpose of a
cost-benefit evaluation, it is essential to calculate benefits using the impact of treatment on
the treated—based on a comparison to counterfactual outcomes rather than pre-treatment
outcomes. Using our upper bound of the treatment impact (calculated by assuming that
patients would have zero labor supply within six months if treatment were not provided), the
average increase in weekly hours worked is 26 hours. In this case the average wage benefit
to patients from treatment is $325 per year, which is considerably larger than the $150
annual per-patient cost of first-line ARV drugs. In addition to ARV drug expenditure,
however, there are several additional costs associated with providing treatment, such as the
costs of lab tests, treatment for opportunistic infections, clinic space, and medical personnel.
AMPATH estimates these costs to be approximately $200 per-patient. Thus, the total patient
wage benefit from providing treatment is roughly equal to the total cost of drugs and other
associated expenses.
However, these are only the simple private wage gains for the patients. Since treatment
expands the time endowment of patients by reducing sick time, patients are also consuming
more leisure. Moreover, while the reduced market labor supply of children due to the
provision of treatment does represent a loss in market income for the household, it is likely
that the increased nonmarket activities of these household members have greater private
value to the household as a whole. As a result, the fact that children reduce their labor
supply suggests that the benefit of treatment is larger than the income gain from the parent’s
increased supply of labor (and leisure). In line with the severity of HIV/AIDS, these results
underscore the importance of maintaining a broad perspective when analyzing the costs and
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benefits of ARV treatment – looking at the intrahousehold allocation of labor is only a first
step. The social benefits from treatment are likely to exceed the private benefits, but valuing
them is a non-trivial challenge. As a result, one purpose of the rough cost-benefit
calculations presented above is to show that the private benefits from treatment alone can
cover the costs of treatment. Indeed, the large labor supply responses we find here are not
the only socio-economic outcomes likely to be affected by ARV therapy. Both HIV/AIDS
and treatment can be expected to influence many other aspects of life within patients’
households. Additional analysis of our data suggests important effects on the nutritional
status of children living with ARV recipients. Schooling and other forms of investment may
also be affected, especially since we find that the incidence of child labor decreases due to
treatment. All of these responses will contribute to an understanding of the comprehensive
welfare consequences of ARV therapy. A detailed analysis of these other non-health
outcomes is part of our future research agenda.
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Figure 1. CD4 Count Before and After Initiation of ARV Therapy
Notes: Figure is generated using CD4 count data in the AMPATH Medical Records System
for all patients receiving ARV therapy at the Mosoriot HIV Clinic. The figure shows the
average CD4 count (solid line) in ten week intervals prior to each point in time before or
after treatment initiation. The figure also shows the 95 percent confidence intervals (dashed
lines) obtained from estimating a linear regression of individuals’ CD4 counts on dummy
variables for each interval (with the omitted interval being the ten weeks prior to treatment
initiation).
Thirumurthy et al. Page 24













Figure 2. Density of Days on Treatment as of Round 1 Interview
Notes: Figure is generated using the date of treatment initiation and the date of the round 1
interview. Vertical bars are shown at 0 days and 100 days. The sample consists of the 191
ARV recipients who appear in both rounds of the household survey data.
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Figure 3. Labor Force Participation Rates Before and After ARV Therapy
Notes: Figure is generated using authors’ survey data and shows the average labor force
participation rate (solid line) in eight week intervals prior to each point in time before or
after treatment initiation. The figure also shows the 95 percent confidence intervals (dashed
lines) obtained from estimating a linear regression of individuals’ labor force participation
on dummy variables for each interval (with the omitted interval being the eight weeks prior
to treatment initiation). The sample consists of the 191 ARV recipients who appear in both
rounds of the household survey data.
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Figure 4. Weekly Hours Worked Before and After ARV Therapy
Notes: Figure is generated using authors’ survey data and shows the average number of
hours worked in the past week (solid line) in eight week intervals prior to each point in time
before or after treatment initiation. The figure also shows the 95 percent confidence intervals
(dashed lines) obtained from estimating a linear regression of individuals’ hours worked on
dummy variables for each interval (with the omitted interval being the eight weeks prior to
treatment initiation). The sample consists of the 191 ARV recipients who appear in both
rounds of the household survey data.
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Figure 5. Weekly Hours Worked by Month of Interview (Men and Women in Random Sample)
Notes: Figure is generated using authors’ survey data and shows the average number of
hours worked in the past week by men (left panel) and women (right panel) according to the
month in which the interview was conducted. The sample used consists of all individuals in
the random sample between the ages of 18–65 years.
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Table 2
Impact of ARV therapy on CD4 count and BMI
(1) (2)
Dependent variable: CD4 BMI
Patient fixed effects
On ARVs at least 1 month 0.38 (2.65)***
On ARVs at least 2 months 0.18 (1.18)
On ARVs at least 3 months 126.72 (10.60)*** −0.10 (0.61)
On ARVs at least 4 months 0.21 (1.29)
On ARVs at least 5 months 0.06 (0.43)
On ARVs at least 6 months −9.11 (0.55) 0.45 (3.25)***
On ARVs at least 7 months 0.29 (2.46)**
On ARVs at least 8 months 0.30 (2.14)**
On ARVs at least 9 months 41.34 (2.31)** 0.53 (3.71)***
On ARVs at least 10 months 0.14 (0.93)
On ARVs at least 11 months 0.22 (1.45)
On ARVs at least 12 months 7.45 (0.37) 0.27 (1.79)*
On ARVs at least 15 months 38.71 (1.31) 0.08 (0.50)
On ARVs at least 18 months 0.42 (0.01) 0.09 (0.52)
Constant 87.48 (12.56)*** 19.53 (275.93)***
Observations 458 2678
R-squared 0.80 0.87
Notes: Absolute value of t-statistics in parentheses (* significant at 10%; ** significant at 5%; *** significant at 1%). Dependent variables are the
CD4+ T cell count (column 1) and body mass index (column 2). Regressions include patient fixed effects. The regressions include all available
post-treatment measures of the CD4 count and BMI for the ARV recipients in our sample. Since not all patients in our sample have one or more
measures of these outcomes, the number of patients used in the regressions is less than the 191 ARVrecepients in our sample.
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Table 5
Reported Reasons for Not Working in the Past Week (Round 1 only)
Random sample ARV patients
Sample size (adults 18–65 years) 1286 191
Did no work in past week 10.8% 24.1%
Reported reason for not working in past week (N=138) (N=46)
 Sick 8% 85%
 Student 54% 0%
 Housework 12% 0%
 No work available 7% 7%
 Other 18% 9%
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Table 7
Estimating the Timepath of Labor Supply after Initiation of ARVs
(1) (2)
Dependent Variable: LFP Hours
Individual fixed effects
3 months prior to ARV initiation 0.083 (1.36) −2.292 (0.25)
On ARVs at least 3 mths ago 0.124 (1.61) 7.277 (2.09)**
On ARVs at least 6 mths ago 0.090 (1.10) 0.438 (0.11)
On ARVs at least 9 mths ago −0.024 (0.30) −0.476 (0.11)
On ARVs at least 12 mths ago −0.072 (0.72) −2.402 (0.39)
On ARVs at least 15 mths ago 0.106 (0.95) 3.741 (0.69)
Constant 0.870 (37.71)*** 35.625 (16.56)***
Observations 2954 2954
R-squared 0.69 0.75
Notes: Errors clustered at the household level for each round and robust t-statistics in parentheses (* significant at 10%; ** significant at 5%; ***
significant at 1%). Dependent variable LFP indicates whether the individual was engaged in any labor market activity in the past week and Hours is
total number of hours devoted to labor market activities in the past week. Regressions include individual fixed effects, round 2 indicator variable,
and month-of-interview indicator variables.
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Table 9
Impact of ARV Therapy for Men and Women
(1) (2) (3) (4)
Dependent variable: LFP Hours LFP Hours
Men Women
Individual fixed effects
Round 2 * Patient on ARVs < 100 days in Round 1 0.048 (0.51) 12.734 (1.69)* 0.218 (2.87)*** 5.263 (1.54)
Round 2 * Patient on ARVs > 100 days in Round 1 0.028 (0.32) 4.564 (0.69) 0.018 (0.36) −0.368 (0.12)
Constant 0.896 (28.95)*** 44.164 (14.47)*** 0.852 (25.83)*** 29.476 (12.15)***
Observations 1408 1408 1546 1546
R-squared 0.69 0.75 0.69 0.70
Notes: Errors clustered at the household level for each round and robust t-statistics in parentheses (* significant at 10%; ** significant at 5%; ***
significant at 1%). Dependent variable LFP indicates whether the individual was engaged in any labor market activity in the past week and Hours is
total number of hours devoted to labor market activities in the past week. Regressions include individual fixed effects, round 2 indicator variable,
and month-of-interview indicator variables.
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Table 10
Impact of ARV Therapy With Attritors in the ARV Sample
(1) (2) (3) (4)
Dependent variable: LFP Hours LFP Hours
Individual fixed effects
Sample includes: deceased deceased & lost to FUP
Round 2 * Patient on ARVs < 100 days in Round 1 0.143 (2.57)** 7.348 (2.34)** 0.111 (1.99)** 6.713 (2.23)**
Round 2 * Patient on ARVs > 100 days in Round 1 −0.011 (0.26) 1.530 (0.56) −0.012 (0.28) 1.542 (0.57)
Constant 0.876 (38.83)*** 35.825 (16.79)*** 0.874 (38.36)*** 35.700 (16.67)***
Observations 2974 2974 2988 2988
R-squared 0.69 0.75 0.70 0.75
Notes: Errors clustered at the household level for each round and robust t-statistics in parentheses (* significant at 10%; ** significant at 5%; ***
significant at 1%). Dependent variable LFP indicates whether the individual was engaged in any labor market activity in the past week and Hours is
total number of hours devoted to labor market activities in the past week. Regressions include individual fixed effects, round 2 indicator variable,
and month-of-interview indicator variables.
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